What's Going On With Eli Lilly Stock On Tuesday?
What's Going On With Eli Lilly Stock On Tuesday?
The updated results corresponding to the final prespecified analysis demonstrate consistent improvement in PFS for patients treated with pirtobrutinib, with a reduction in risk of relapse, disease, or death by 46% compared to IdelaR or BR.On Monday, Eli Lilly And Co (NYSE:LLY) announced results from the Phase 3 BRUIN CLL-321 trial evaluating pirtobrutinib in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) previously treated with a covalent BTK inhibitor.
週一，禮來公司（紐交所：LLY）宣佈了第三階段BRUIN CLL-321試驗的結果，該試驗評估了在之前接受過共價BTk抑制劑治療的慢性淋巴細胞白血病或小淋巴細胞淋巴瘤（CLL/SLL）成年患者中使用pirtobrutinib。
The study's primary endpoint of progression-free survival (PFS) was met at primary analysis, demonstrating pirtobrutinib was superior to the investigator's choice of idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR).
研究的主要終點無進展生存期（PFS）在主要分析中達成，證實pirtobrutinib優於研究者選擇的idelalisib加利妥昔單抗（IdelaR）或班達穆斯汀加利妥昔單抗（BR）。
Also Read: As Eli Lilly Shares Gain Over 35% YTD, Drugmaker Announces $15B Share Buyback Program And Boosts Dividend By 15%
另外閱讀：隨着禮來股票年初至今上漲超過35%，這家制藥公司宣佈了價值150億美元的股票回購計劃，並提高了15%的股息。
The updated results corresponding to the final prespecified analysis demonstrate consistent improvement in PFS for patients treated with pirtobrutinib, with a reduction in risk of relapse, disease, or death by 46% compared to IdelaR or BR.
相應於最終預設分析的更新結果顯示，接受pirtobrutinib治療的患者在無進展生存期（PFS）方面一致改善，與IdelaR或BR相比，復發、疾病或死亡的風險降低了46%。
These data will be presented at the American Society of Hematology Annual Meeting and Exposition.
這些數據將在美國血液學會年會和博覽會上公佈。
BRUIN CLL-321 enrolled 238 randomized patients to receive pirtobrutinib monotherapy (n=119) or the investigator's choice of IdelaR or BR (n=119).
BRUIN CLL-321試驗招募了238名隨機患者，以接受pirtobrutinib單藥治療（n=119）或研究者選擇的IdelaR或BR（n=119）。
Pirtobrutinib also demonstrated clinically meaningful improvements in other secondary endpoints such as investigator-assessed PFS (median PFS: 15.3 vs. 9.2 months), event-free survival (EFS) (median EFS: 14.1 vs. 7.6 months), and time to next treatment (TTNT) or death (median TTNT: 23.9 vs. 10.9 months).
Pirtobrutinib在其他次要終點方面也顯示出臨床上具有意義的改善，例如研究者評估的PFS（中位PFS：15.3月對比9.2月）、事件無生存期（EFS）（中位EFS：14.1月對比7.6月）以及到下次治療（TTNT）或死亡的時間（中位TTNT：23.9月對比10.9月）。
Specifically, among patients in the control arm who were eligible for crossover, 76% (n=50/66) crossed over to receive pirtobrutinib. Multiple analyses that adjust for the crossover effect demonstrate trends favoring pirtobrutinib.
具體來說，在對照組中有76%（n=50/66）符合交叉治療條件的患者接受了pirtobrutinib治療。調整交叉效應的多次分析顯示出有利於pirtobrutinib的趨勢。
The overall safety profile for patients treated with pirtobrutinib in BRUIN CLL-321 was consistent with safety data from the Phase 1/2 BRUIN study, including adverse events of special interest.
在BRUIN CLL-321中，接受pirtobrutinib治療的患者的整體安全性特徵與第一/二階段BRUIN研究中的安全性數據一致，包括特別關注的不良事件。
Pirtobrutinib is approved as Jaypirca under the FDA's Accelerated Approval pathway for adult patients with CLL/SLL who have received at least two prior lines of therapy and adult patients with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy.
pirtobrutinib已在FDA的加速批准途徑下作爲Jaypirca獲批，用於接受至少兩次先前治療的成人CLL/SLL患者，以及在接受至少兩次系統治療後復發或難治的成年環狀細胞淋巴瘤患者。
Price Action: LLY stock is down by 0.14% at $802.42 at the last check Tuesday.
價格動態：LLY股票在週二最後一次檢查時下跌0.14%，報802.42美元。
- United Natural Foods Beats Q1 Estimates On Positive Volume Trends, Lifts FY25 Guidance
- 聯合原生態食品超出了第一季度的預期，受積極的成交量趨勢影響，提高了2025財年的指導意見
Photo by Jonathan Weiss via Shutterstock
照片由Jonathan Weiss提供，通過Shutterstock
譯文內容由第三人軟體翻譯。
